JPMorgan Chase & Co. Issues Positive Forecast for TransMedics Group (NASDAQ:TMDX) Stock Price

TransMedics Group (NASDAQ:TMDX) had its price target increased by research analysts at JPMorgan Chase & Co. from $114.00 to $149.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 10.84% from the stock’s current price.

Several other equities analysts have also weighed in on TMDX. Piper Sandler lifted their price objective on TransMedics Group from $140.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday. Needham & Company LLC raised their price target on shares of TransMedics Group from $166.00 to $174.00 and gave the company a “buy” rating in a report on Wednesday. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, February 14th. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Finally, Morgan Stanley lifted their target price on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Six analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $150.67.

TransMedics Group Trading Down 2.4%

Shares of TMDX traded down $3.35 during trading hours on Wednesday, hitting $134.43. The stock had a trading volume of 1,648,105 shares, compared to its average volume of 751,713. TransMedics Group has a 12-month low of $62.07 and a 12-month high of $156.00. The firm has a market cap of $4.59 billion, a P/E ratio of 54.15 and a beta of 2.06. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. The company’s fifty day simple moving average is $132.98 and its 200 day simple moving average is $126.22.

Insiders Place Their Bets

In related news, CFO Gerardo Hernandez sold 920 shares of TransMedics Group stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the sale, the chief financial officer owned 15,064 shares of the company’s stock, valued at $2,103,235.68. The trade was a 5.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David Weill sold 5,000 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the transaction, the director directly owned 12,134 shares of the company’s stock, valued at approximately $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors have recently made changes to their positions in TMDX. Intech Investment Management LLC raised its stake in shares of TransMedics Group by 28.9% in the 2nd quarter. Intech Investment Management LLC now owns 34,389 shares of the company’s stock valued at $4,608,000 after purchasing an additional 7,713 shares in the last quarter. Nordea Investment Management AB bought a new stake in TransMedics Group in the third quarter valued at about $4,070,000. Peregrine Capital Management LLC raised its stake in TransMedics Group by 16.5% during the third quarter. Peregrine Capital Management LLC now owns 68,406 shares of the company’s stock valued at $7,675,000 after buying an additional 9,676 shares in the last quarter. Intrust Bank NA bought a new position in TransMedics Group during the 2nd quarter worth approximately $747,000. Finally, Lisanti Capital Growth LLC grew its position in shares of TransMedics Group by 62.0% in the 3rd quarter. Lisanti Capital Growth LLC now owns 56,901 shares of the company’s stock worth $6,384,000 after acquiring an additional 21,771 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Key TransMedics Group News

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Q4 results showed a large beat: EPS of $2.62 vs. consensus $0.41 and revenue of $160.8M (+32% YoY). Management provided materials and slides alongside the release. MarketBeat: Earnings Report
• Positive Sentiment: Company issued FY2026 revenue guidance of roughly $727M–$757M (vs. consensus ~$722.8M), signaling continued top‑line growth for the year. PR Newswire: Financial Results & Guidance
• Positive Sentiment: TransMedics outlined a 20–25% revenue growth target for 2026 and highlighted progress on OCS programs and European expansion—key operational drivers for future unit growth. Seeking Alpha: 2026 Revenue Target & OCS Programs
• Positive Sentiment: Analyst upgrades: Needham raised its price target to $174 (Buy) and Piper Sandler lifted its target to $160 (Overweight), reflecting increased upside expectations. Benzinga: Needham Price Target Benzinga: Piper Sandler Price Target
• Positive Sentiment: Market reaction coverage noted a surge after the earnings beat and solid guidance, confirming short‑term bullish sentiment among some traders. Investing.com: Market Reaction
• Neutral Sentiment: Detailed analyses and the full earnings‑call transcript are available for investors who want to dig into unit economics, margin drivers and the cadence of OCS commercialization. Seeking Alpha: Earnings Call Transcript
• Neutral Sentiment: Analyst notes and metric comparisons (Zacks) break down how key metrics stacked up vs. estimates—useful for modeling but not new headline news. Zacks: Key Metrics vs Estimates

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.